Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
Ovid Therapeutics Inc. (OVID) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2023 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates"
05/05/2023 8-K Quarterly results
Docs: "Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates"
03/13/2023 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results"
11/08/2022 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights"
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results • Ovid executing on its strategy to build a leading epilepsy pipeline • OV329 expected to enter the clinic in 2022 • Organization reshaped to reduce personnel by 20% and increase operational efficiency • Targeted business development continues to support the pipeline NEW YORK, March 15, 2022 -- Ovid Therapeutics Inc. , a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. "Ovid is disciplined in our focus to become a leader in epilepsy therapies. We are..."
08/16/2021 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights"
11/12/2020 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update"
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
11/08/2019 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency Reduction with Prolonged Treatment in Difficult-to-Treat Patient Population"
08/07/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Ovid Therapeutics Reports First Quarter 2019 Financial Results Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN Top Science Press Conference"
03/07/2019 8-K Quarterly results
11/08/2018 8-K Quarterly results
Docs: "Phase 1b/2a trial in adults with severe seizures: All patients have completed their last visit in this 12-week study, which enrolled 18 patients across a broad spectrum of DEE. These patients have persistent, severe seizures despite prior treatment with multiple anti-epileptic medications. Ovid will report the results in the fourth quarter of 2018. The primary endpoint of this study is safety and tolerability. Secondary and exploratory endpoints include evaluation of pharmacokinetic parameters, change from baseline in seizure frequency and 24-hydroxycholesterol levels. Plasma 24HC is being further assessed as a potential biomarker for OV935. • Pediatric and extension studies: In the third quarter, Ovid and Takeda initiated two Phase 2 clinical trials of OV935 for pediatric patients ..."
05/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress"
03/29/2018 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress"
11/09/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 9, 2017 OVID THERAPEUTICS INC. Delaware 001-38085 46-5270895 1460 Broadway, Suite 15044 New York, New York 10036 Registrant's telephone number, including area code: 661-7661 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencem...",
"Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress"
08/10/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress"
06/14/2017 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy